XETRA - Delayed Quote EUR

Amgen Inc. (AMG.DE)

252.55

-1.90

(-0.75%)

As of 10:54:08 AM GMT+2. Market Open.

Sector Update: Health Care Stocks Rise Monday Afternoon

Health care stocks were higher Monday afternoon, with the NYSE Health Care Index rising 0.4% and the

PREMIUM
MT Newswires 2 days ago

IRWD

AMGN

PFE
Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit

Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

Pharmaceutical Technology 2 days ago

AMGN

GLDAF
Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC

The randomised, controlled study aims to assess the therapy’s safety and efficacy.

Clinical Trials Arena 2 days ago

AMGN
Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug

ZURICH (Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its blockbuster medicine, Enbrel (etanercept). Sandoz alleges Amgen blocked competition from more cost-effective biosimilar competitors, including Sandoz etanercept biosimilar, Erelzi, by unlawfully purchasing and using certain patent rights to entrench its dominant market position. Amgen said it did not comment on pending litigation.

Reuters 3 days ago

AMGN
Amgen (AMGN) Gains But Lags Market: What You Should Know

In the latest trading session, Amgen (AMGN) closed at $285.92, marking a +1.6% move from the previous day.

Zacks 5 days ago

AMGN
Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Health care stocks advanced late Friday afternoon with the NYSE Health Care Index adding 1.8% and th

PREMIUM
MT Newswires 5 days ago

AMGN
Sector Update: Health Care Stocks Gain in Afternoon Trading

Health care stocks advanced Friday afternoon, with the NYSE Health Care Index adding 1.9% and the He

PREMIUM
MT Newswires 5 days ago

AMGN
Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA

Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for its DeLLphi-304 trial assessing IMDELLTRA for small cell lung cancer. These product advancements likely buoyed the company's recent quarterly price increase of 7.31%. Moreover, broader market movements contributed to shifts in Amgen's stock. Notably, the volatile trading activity, which saw the Dow and other indexes rally, subdued inflation data, and mixed economic...

Simply Wall St. 5 days ago

AMGN
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy met its primary endpoint at a planned interim analysis. IMDELLTRA demonstrated statistically significant and clinically meaningful improvement in overall survival (OS) compared to local standard-of-care (SOC) chemotherapy.

PR Newswire 5 days ago

AMGN
Pharma’s US manufacturing moment: Where companies are making the biggest moves

The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.

Pharma Voice 6 days ago

AMGN

LLY

NVO
The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

Zacks 7 days ago

PCRX

SRPT

EWTX
Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner.

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits significantly in the years ahead.

Barrons.com 7 days ago

AMGN
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 8 days ago

AMGN
3 Dividend Stocks to Buy and Hold for the Next Decade

What should investors do when stocks are tanking over the short term? Three Motley Fool contributors think they've found great dividend stocks to own for the long term that pay you to wait for better days. Here's why they picked AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), and Eli Lilly (NYSE: LLY).

Motley Fool 10 days ago

ABBV

AMGN

LLY
2 Dividend Stocks to Buy Hand Over Fist in April

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a result, cash can be in short supply. Let's take a look at two outliers with dividend policies that have looked especially attractive lately -- pharmaceutical companies Amgen (NASDAQ: AMGN) and AbbVie (NYSE: ABBV). Amgen's involvement in the high-demand obesity drugs race has attracted attention recently, but the pharmaceutical sector star has been on the radar of clever investors for years.

Motley Fool 11 days ago

AMGN

ABBV
Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA approval of UPLIZNA for treating Immunoglobulin G4-related disease (IgG4-RD). This approval, alongside the Breakthrough Therapy Designation granted by the FDA, reflects high unmet medical needs being addressed, which could have positively influenced investor sentiment. Despite broader market declines, including a 5% drop in the Nasdaq Composite due to trade tensions,...

Simply Wall St. 12 days ago

AMGN
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

Zacks 12 days ago

AMGN
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Amgen (AMGN) concluded the recent trading session at $310.09, signifying a +1.44% move from its prior day's close.

Zacks 13 days ago

AMGN

^GSPC
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. Compared to the S&P 500's (SNPINDEX: ^GSPC) 4.8% tumble, Catalyst Pharmaceuticals' (NASDAQ: CPRX) 1.5% drop was mild, as was Veeva Systems' (NYSE: VEEV) 2% slide.

Motley Fool 13 days ago

AMGN

^GSPC
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD). IgG4-RD is a chronic and debilitating immune-mediated inflammatory condition that can affect multiple organs. The FDA granted Breakthrough Therapy Designation to UPLIZNA for the treatment of IgG4-RD, recognizing the high unmet medical need in this serious condition and the medicine's potential

PR Newswire 13 days ago

AMGN

Performance Overview

Return	AMG.DE	S&P 500 (^GSPC)
YTD	+0.93%	-10.30%
1-Year	+5.26%	+5.05%
3-Year	+18.07%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMG.DE)

Sector Update: Health Care Stocks Rise Monday Afternoon

Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit

Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC

Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug

Amgen (AMGN) Gains But Lags Market: What You Should Know

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Sector Update: Health Care Stocks Gain in Afternoon Trading

Amgen (NasdaqGS:AMGN) Clinical Trial Success In SCLC Treatment With IMDELLTRA

IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER

Pharma’s US manufacturing moment: Where companies are making the biggest moves

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner.

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

3 Dividend Stocks to Buy and Hold for the Next Decade

2 Dividend Stocks to Buy Hand Over Fist in April

Amgen (NasdaqGS:AMGN) Gains FDA Approval For UPLIZNA In Treating IgG4-Related Disease

AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication

Amgen (AMGN) Rises As Market Takes a Dip: Key Facts

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE

Performance Overview